Emyria and MMA launch MDMA-assisted therapy program for PTSD
Released
Released
Announcement PDF
ASX Announcement
05/05/2021
Emyria and Mind Medicine Australia to launch psychedelic-assisted
therapy program (EMDMA-001) for PTSD
Highlights:
●
Emyria and Mind Medicine Australia announce their first psychedelic-assisted
therapy care program (EMDMA-001) for sufferers of treatment resistant post
traumatic stress disorder (PTSD)
●
EMDMA-001 has been modelled on a major Phase III clinical trial developed by
the Multidisciplinary Association for Psychedelic Studies (MAPS)
●
Pending successful ethics review and the finalisation of all logistics,,
EMDMA-001 will commence with a Phase II, open-label clinical trial of
MDMA-assisted psychotherapy at Emyria’s fit-for-purpose clinic in Melbourne
before expanding to other sites
●
EMDMA-001 will utilise specially-trained psychotherapists graduating from
Mind Medicine Australia’s first Certificate in Psychedelic-Assisted Therapy
(CPAT) training program end of this month
●
EMDMA-001 will leverage Emyria’s established clinical infrastructure and
data capture technology to provide safe patient access while also generating
high quality, Real-World Evidence to inform future development
●
It is expected that this first program will be an important first step towards
delivering safe, accredited, cost-effective, scalable and evidence-based,
psychedelic-assisted therapy services across Australia
Emyria Limited (ASX: EMD) (Emyria or the Company), an innovative drug
development and clinical services company, is pleased to announce the launch of
EMDMA-001, a psychedelic-assisted therapy program targeting Posttraumatic Stress
Disorder (PTSD) developed with partner Mind Medicine Australia. [Ann 19 Nov 20]
As a first step, and pending ethics approval, Emyria will Sponsor a major,
independently monitored, clinical trial targeting treatment resistant PTSD with
evidence-based MDMA-assisted therapy .
A key priority of this first program is to help evaluate the long-term safety, efficacy
and cost benefits of MDMA-assisted psychotherapy. Such evidence is needed, along
with fit-for-purpose clinical infrastructure and trained therapists in order to
deliver psychedelic-assisted care in a safe, standardised and scalable way.
1
Emyria’s Managing Director, Dr. Michael Winlo says: “There is growing
international interest in the promise of psychedelic-assisted therapies for treating
our most challenging mental health conditions. However, the care model and
the drug intervention are intrinsically linked. This means any treatment will
require a properly prepared and equipped clinical service - including specially
trained clinicians and therapists. We also require more robust clinical evidence
to guide future innovation and development in this space.
At Emyria, our strength is in providing safe access to unregistered treatments
while also generating clinical evidence. To date, we have cared for over 4,000
patients with major unmet needs (including more than 80 patients suffering with
treatment resistant PTSD) and collected high-quality Real-World Evidence.
Emyria’s clinical advisory, site network and data infrastructure is uniquely
positioned to support safe and scalable psychedelic-assisted therapy, much like
we have demonstrated and accomplished with cannabinoid medicines.
Our goal is to build a unique clinical database that we hope can help optimise
the development of existing and novel treatments while also allowing Emyria
and our partner, Mind Medicine Australia to become the trusted and accredited
clinical service of choice.”
Mind Medicine Australia’s Chairman, Peter Hunt AM says: “We are delighted to
be working with Emyria on developing the pathway for the use of evidence-based
psychedelic assisted therapies for the treatment of key mental illnesses in
Australia.
Post traumatic stress disorder is a debilitating condition and existing modalities
(primarily pharmaceutical medicines and psychotherapy) can have relatively low
remission outcomes and – in the case of the pharmaceuticals – can have nasty
side effects.
MDMA assisted psychotherapy is showing very high remission rates in overseas
trials and has also been shown to have high levels of safety and to be
non-addictive when used in medically controlled environments. Negative side
effects have also been minimal. Therapists have been specifically trained for this
work through our certificate course and appropriate protocols developed with
Emyria.
The trial approach being taken by Emyria is also consistent with the Federal
Government’s recently announced grant of $15 million for trials utilising
hallucinogens or stimulant drugs supported by psychotherapy for treatment
resistant mental illnesses.”
2
Mind medicine Australia (www.mindmedicineaustralia.org) is an Australian
registered charity that seeks to alleviate the suffering caused by mental illness in
Australia through expanding the treatment options. The organisation is focused
on the development of safe and effective psychedelic-assisted therapies to cure a
range of mental illnesses.
Mental health is a growing health concern
Mental health currently tops the list of chronic health conditions in Australia with
4.8 million people, or 20.1% of all Australians affected. [1]
Veteran’s are particularly affected by PTSD
Mental health is a particular concern of veterans as evidenced by the recent
launch of a Royal Commission into Defence and Veteran Suicide by Prime Minister
Scott Morrison. [2] While, between five and ten percent of the general community
are likely to develop PTSD at some point in their lives, rates amongst veterans are
estimated close to 20 percent. [3]
Psychedelic-assisted therapy offers potential
The past Chair of the Australian Defence Force (1998-2002), Admiral Chris Barrie,
recently encouraged the Australian Government to consider the clinical use of
specific psychedelics to help veterans recovering from trauma. [4]
In fact, there is now a strong and emerging body of international evidence that
shows that substances such as ketamine, psilocybin, and
3,4-methylenedioxymethamphetamine (MDMA), when used in a controlled
environment and supported by psychotherapy, offer a promising new approach to
effectively treating pernicious mental illnesses that are resistant to first-line
treatments. [5]
The Multidisciplinary Association for Psychedelic Studies (MAPS) recently
announced results of a Phase 3 trial of MDMA-assisted therapy for PTSD and
reported a significant reduction in PTSD symptoms compared to those who
received placebo with therapy (p<0.0001). 67% of the group who received MDMA,
compared to 32% of the group who received placebo, no longer qualified for a
PTSD diagnosis after three treatment sessions. [6]
Psilocybin-assisted therapy for treatment resistant depression and major
depressive disorder and MDMA-assisted therapy for PTSD have been granted
‘Breakthrough Therapy’ status by the US Food and Drug Administration (FDA). [7]
Beyond EMDMA-001, Emyria plans to further explore other MDMA- and
psilocybin-assisted therapy programs in treating disorders such as depression and
substance abuse as mentioned in ASX release 19 November 2020.
3
Australian Federal government commits $15m to “Innovative Therapies for
Mental Illness”
In recognition of the promise of this new field but also the great need for more
clinical evidence, on 17 March 2021, Federal Health Minister, Greg Hunt, announced
$15m in new funding for “Australian medical research projects that use clinical
trials to assess the safety and efficacy of innovative therapies using hallucinogens
and stimulant drugs supported by psychological/ psychiatric care for treatment
resistant mental illness, compared to standard therapies.” [8]
EMDMA-001 to address major challenges in MDMA-assisted therapy
Novel research and specialised training are needed because of the way
MDMA-assisted therapy is delivered. The treatment is unlike traditional
psychotherapy or psychopharmacology. The psychotherapy is deeply intertwined
with pharmacological intervention.
In general, MDMA-assisted therapy involves three general stages:
●
●
●
Preparation – in which the therapist and patient get to know one
another and build trust
Administration & Monitoring – the patient, usually lying down and
wearing an eye mask, is given a dose of MDMA and supported by two
therapists during each session – which can last 6 to 8 hours
Integration – the next day, and at weekly intervals for on average 3
occasions, the patient and therapist discuss the experience and how
to integrate any insights into behavioural change
Some patients may need to repeat the cycles above and a clinical service must
be prepared to support patients through the full experience and beyond.
Given the length of individual therapy sessions and the fact some patients may
need to repeat part, or all of these cycles, there is a major need for properly
prepared clinical services and specially trained psychotherapists to support
psychedelic-assisted therapy at scale.
Further, any future regulation of these therapies is likely to consider the
capabilities of the clinical service providing these treatments.
TGA position on psychedelics
There is an active rescheduling proposal from Mind Medicine Australia before the
TGA so that medical-grade psilocybin and MDMA can be more easily used as
clinical therapies in medically controlled environments for the treatment of key
mental illnesses. The rescheduling, if successful, would move these medicines to
Schedule 8 (which deals with Controlled Medicines), the same category as
THC-containing cannabinoid medicines.
4
A final decision on rescheduling was recently delayed as the Scheduling Delegate
has decided to seek further advice in relation to psilocybin and MDMA. This will
include an independent expert review into the therapeutic value, risks and benefits
to public health outcomes for these substances as well as seeking additional advice
from the Advisory Committee on Medicines Scheduling following the review. [8]
Until rescheduling occurs, patient access to these therapies is limited to
ethics-approved clinical trials (with the possible exception of Victoria which already
has a permit for approvals on a case-by-case basis).
Next steps:
The Company believes through its non-exclusive partnership with Mind Medicine
Australia it is uniquely positioned to deliver the requisite clinical services while also
generating robust and ethically sourced clinical evidence to advance the field.
The first cohort of trained therapists will graduate this month from Mind Medicine
Australia’s therapist training course and the Company has already equipped a
fit-for-purpose facility. A protocol is being finalised and is expected to be submitted
to ethics soon with all the necessary regulatory steps carefully observed. The
company will provide further updates as the program advances.
This announcement has been approved and authorised for release by the Board of
Emyria Limited. For further information:
Dr Michael Winlo
Managing Director
(08) 6559 2800
mwinlo@emyria.com
Lexi O’Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au
Peter Hunt
Chairman
+61 (0) 419 271 483
peter@mindmedicineaustralia.org
REFERENCES
[1] https://www1.racgp.org.au/newsgp/clinical/mental-health-issues-increasing-among-australians
[2] https://www.pm.gov.au/media/establishment-royal-commission-defence-and-veteran-suicide
[3] https://www.dva.gov.au/health-and-treatment/injury-or-health-treatments/mental-health-care
/post-traumatic-stress-disorder
[4] https://www.abc.net.au/radio/programs/conversations/chris-barrie-admiral-defence-force-pts
d-psychedelics/13240466
[5] https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/15-million
-for-development-of-innovative-therapies-for-mental-illness
[6]https://maps.org/news/media/9122-maps-phase-3-trial-of-mdma-assisted-therapy-for-ptsd-achiev
es-successful-results-for-patients-with-severe-chronic-ptsd
[6] https://maps.org/news/media/6786-press-release-fda-grants-breakthrough-therapy-designation
-for-mdma-assisted-psychotherapy-for-ptsd,-agrees-on-special-protocol-assessment-for-phase-3-trials
[7] https://www.nhmrc.gov.au/funding/find-funding/mrff-2021-innovative-therapies-mental-illness
-grant-opportunity-go-id-4726
[8] https://www.tga.gov.au/update-psilocybin-and-mdma-scheduling
5
About Emyria (www.emyria.com)
Emyria Limited is a data-backed, drug development company. Emyria’s Treatments
target unmet needs and are focused on obtaining approval from major global regulators.
Emyria’s drug development programs are informed by insights generated from extensive
analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with
patients across Emyria’s independent clinical services (Emerald Clinics www.emeraldclinics.com.au)
Emyria Data provides deep treatment insights and is therefore a source of unique IP,
strategically designed drug development and personalised care programs.
About Mind Medicine Australia (https://mindmedicineaustralia.org)
Mind Medicine Australia (“MMA”) is a registered charity that was set up to help alleviate
the suffering caused by mental illness in Australia through expanding the treatment
options available to medical practitioners and their patients. MMA is focused on
developing the ecosystem in Australia to enable psychedelic-assisted therapies to be
available through the medical system as safe and effective treatments for a range of
mental illnesses. The organisation operates as a nexus between medical practitioners,
academia, government, regulatory bodies, philanthropists, and other partners.
MMA is particularly focused on the clinical application of medicinal psilocybin and
medicinal MDMA as part of therapy for key mental illnesses such as Depression, Post
Traumatic Stress Disorder and Substance Abuse. MMA’s strategy focuses on awareness
building amongst all key stakeholder groups such as medical practitioners, regulators,
researchers, patients and carers; the training of therapists in these modalities; the
development of a Centre of Excellence in Emerging Mental Health Therapies; and all the
logistics involved in developing the right ethical and legal framework, the manufacturing
of these medicines and the rollout of specialist clinics.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the
Company, the company’s strategy, future operations, and other statements containing the words
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors, including: the Company’s
ability to successfully develop its product candidates and timely complete its planned clinical
programs and the Company’s ability to obtain marketing approvals for its product candidates. In
addition, the forward-looking statements included in this press release represents the Company’s
views as of the date hereof. The Company anticipates that subsequent events and developments
will cause the Company’s views to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company specifically disclaims any
obligation to do so. These forward-looking statements should not be relied upon as representing
the Company’s views as of any date subsequent to the date hereof.
6
Share your feedback
Discover